EP MedSystems Reports
Second Quarter Financial Results
WEST BERLIN, N.J.--(BUSINESS WIRE)--Aug. 15, 2006--EP
MedSystems, Inc. (NASDAQ: EPMD - News),
a market leader in electrophysiology products
used to diagnose and treat certain types of
cardiac rhythm disorders, today announced
financial results for the three and six months
ended June 30, 2006. For the six months ended
June 30, 2006, revenues were $7,390,000, a
decrease of 10% from the $8,231,000 reported in
the same period last year. Sales of our
consumable products were up 2% in the first six
months of 2006 over the same six months of 2005
primarily as a result of a 31% increase in sales
of ViewFlexÔ
ultrasound catheters. The gross margin
percentage for the six months ended June 30,
2006 remained flat compared to the comparable
period of 2005. The net loss for the six months
ended June 30, 2006 was $3,708,000 or ($0.13)
per share, compared to $2,573,000 or ($0.10) per
share in the prior year.
The Company finished the quarter with cash and cash equivalents of
$11,409,000.
Revenues for the quarter were $3,312,000, a decrease of 30% from the
$4,755,000 reported for the three months ended June
30, 2005. Sales of our consumable products were up
18% in the second quarter of 2006 over the same
quarter in 2005 primarily as a result of a 37%
increase in sales of our ViewFlexÔ
ultrasound catheters. The gross margin for the three
months ended June 30, 2006 was flat compared to the
same period in 2005. The net loss for the quarter
was $2,213,000, compared to the $1,166,000 reported
in 2005. The basic and diluted loss per share for
the three months ended June 30, 2006 was ($0.07),
which compared to ($0.05) for the comparable period
in 2005.
Included in the second quarter’s loss was an accrual
of $345,000 which reflects management’s estimate of
a fine to be levied by the U.S. Department of
Commerce for export violations. The Company has had
an ongoing investigation by the United States
government concerning these violations for quite
some time.
David
Jenkins, EP MedSystems’ Chairman, President and
Chief Executive Officer commented, “We
are disappointed in the second quarter sales results
and are taking steps to address this through our
search for a new CEO with a strong sales and
marketing background. In addition, we have made
good progress in resolving investigations by federal
government agencies concerning export violations and
hope to fully resolve these matters shortly. We
believe that both of these steps will allow us to
focus on operational execution in the quarters
ahead.”
Corporate Conference
Call
EP MedSystems' management will host a conference
call today, August 15, 2006, at 10:00 a.m. EST to
review the second quarter financial results and
other corporate events. David Jenkins, Chairman,
President and Chief Executive Officer, will host the
call and take part in a Q & A session.
The call can be accessed by dialing (800) 240-4186
and giving the company name, "EP MedSystems".
Participants are asked to call the number
approximately 10 minutes before the conference call
begins. A replay of the conference call will be
available two hours after the call for the following
five days by dialing (800) 405-2236 and entering the
following pass code: 11067822 #.
The call can also be accessed live on the web at
www.epmedsystems.com in the investor relations
area of the site or by going to
http://www.mkr-group.com.
About EP MedSystems:
EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac rhythm disorders. The Company's EP product line includes the EP-WorkMate® Electrophysiology Workstation with RPM(TM) Real-time Position Management(TM) navigation technology, the EP-4(TM) Computerized Cardiac Stimulator, fixed and deflectable diagnostic electrophysiology catheters and related disposable supplies, the ALERT® System and ALERT family of internal cardioversion catheters, and the ViewMate® intracardiac ultrasound catheter imaging. For more information, visit our Website at www.epmedsystems.com.
Forward Looking Statements:
This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Forward-looking statements include information concerning our possible or assumed future results of operations and statements preceded by, followed by or including the words "believes", "expects", "anticipates", "intends", "plans", "estimates", or similar expressions. Such forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of market acceptance of our products and level of sales, uncertainty of future profitability and future liquidity needs; possible fines costs or penalties that may be incurred in connection with the government inquires and investigations and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual Report filed on Form 10-K and quarterly reports filed on Form 10-Q.
EP MedSystems cautions investors and others to review the cautionary statements set forth in this press release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on this press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.
###
Other highlights reported for the quarter
and six months include:
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
|
June 30, |
|
June 30, |
|
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
Net Sales |
|
$3,312,000 |
|
$4,755,000 |
|
$7,390,000 |
|
$8,231,000 |
|
Cost of products sold |
|
1,244,000 |
|
1,750,000 |
|
2,832,000 |
|
3,028,000 |
|
Gross Profit |
|
2,068,000 |
|
3,005,000 |
|
4,558,000 |
|
5,203,000 |
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
Sales and marketing |
|
2,556,000 |
|
2,174,000 |
|
4,970,000 |
|
4,303,000 |
|
General and administrative |
|
1,093,000 |
|
1,389,000 |
|
1,957,000 |
|
2,260,000 |
|
Research and development |
|
681,000 |
|
589,000 |
|
1,379,000 |
|
1,173,000 |
|
Total Operating Expenses |
|
4,330,000 |
|
4,152,000 |
|
8,306,000 |
|
7,736,000 |
|
Loss from operations |
|
(2,262,000) |
|
(1,147,000) |
|
(3,748,000) |
|
(2,533,000) |
|
|
|
|
|
|
|
|
|
|
|
Interest income (expense) |
|
49,000 |
|
(19,000) |
|
40,000 |
|
(40,000) |
|
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
$(2,213,000) |
|
$(1,166,000) |
|
$(3,708,000) |
|
$(2,573,000) |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share |
|
$(0.07) |
|
$(0.05) |
|
$(0.13) |
|
$(0.10) |
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding |
|
30,365,236 |
|
25,814,176 |
|
28,277,500 |
|
25,709,053 |
|
Balance Sheet Data |
|
At June 30, 2006 |
|
At June 30, 2005 |
|
Cash and cash equivalents |
$11,409,000 |
|
$7,716,000
$7,716,000 |
|
Working capital |
|
14,150,000 |
|
10,608,000 |
|
Total assets |
|
21,082,000 |
|
18,020,000 |
|
Total liabilities |
|
6,496,000 |
|
7,041,000 |
|
Shareholders equity |
|
14,586,000 |
|
10,979,000 |
For Further Information Contact:
Matthew C. Hill, Chief Financial Officer
(856) 753-8533
MKR Group, LLC
Charles Messman, Todd Kehrli
(818)556-3700
|